Paper Details

  1. Home
  2. Paper Details

MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.

Author: KuwataKiyoko, NakagawaKazuhiko, OkamotoIsamu, OkamotoKunio, TakezawaKen, TanizakiJunko, YamaguchiHaruka

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Crizotinib is a tyrosine kinase inhibitor that is being studied for the treatment of lung cancer. This study examined the antitumor action of crizotinib in lung cancer cells that are positive or negative for MET amplification or mutation.
Paper Details　
Original Abstract of the Article :
Tyrosine kinase inhibitors (TKIs) targeted to MET are undergoing clinical trials in patients with solid tumors, but the precise mechanism of the antitumor activity of these drugs remains unclear. We examined the antitumor action of the MET-TKI crizotinib (PF-02341066) in lung cancer cells that are p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/21716144

データ提供：米国国立医学図書館（NLM）

MET Kinase Inhibitor: A Targeted Approach to Lung Cancer Treatment

Lung cancer remains a major health challenge, and finding effective therapies is crucial for improving patient survival. This study examines the antitumor activity of a MET tyrosine kinase inhibitor (TKI) called crizotinib in lung cancer cells. The researchers explored the specific mechanisms of action of this drug, focusing on its effectiveness against lung cancer cells with different MET alterations, such as amplifications or mutations.

Targeted Therapy Shows Promise in Lung Cancer Treatment

The study demonstrated that crizotinib exhibits differential antitumor effects in lung cancer cells based on the presence of MET alterations. These findings suggest that targeting specific molecular pathways within cancer cells can be an effective approach to treating the disease. The research provides valuable information for understanding the role of MET alterations in lung cancer and the potential of targeted therapies in treating this aggressive disease.

Precision Medicine: Tailoring Treatment to Individual Needs

This research showcases the promise of precision medicine in cancer treatment. By understanding the specific molecular characteristics of a patient's tumor, doctors can tailor treatment plans that are most likely to be effective. The study highlights the importance of identifying MET alterations in lung cancer patients and considering the use of MET-targeted therapies like crizotinib.

Dr.Camel's Conclusion

This study reminds us that the vast desert of cancer research is constantly evolving, revealing new targets and strategies for treatment. Just as a camel adapts to the ever-changing landscape, we must adapt our approaches to cancer therapy, embracing targeted treatments that offer individualized solutions. This research highlights the potential of MET kinase inhibitors as a valuable tool in the fight against lung cancer.

Date :
  1. Date Completed 2012-01-17
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

21716144

DOI: Digital Object Identifier

S1556-0864(15)33198-1

Related Literature

Article Analysis
・Effects of crizotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.